Temporal trends in polypharmacy and hyperpolypharmacy in older new zealanders over a 9-year period: 2005-2013

Gerontology

Volumn 61, Issue 3, 2015, Pages 195-202

  Nishtala, Prasad S ^a   Salahudeen, Mohammed Saji ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Elderly; Hyperpolypharmacy; Older people; Polypharmacy; Prevalence; Trends

Indexed keywords

AFRICAN; AGED; AGING; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE POLICY; HUMAN; HYPERPOLYPHARMACY; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; NEW ZEALAND; NEW ZEALANDER; POLYPHARMACY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS; SOUTH AND CENTRAL AMERICA; UNLICENSED DRUG USE; VERY ELDERLY; CLINICAL PHARMACOLOGY; GERIATRICS; POTENTIALLY INAPPROPRIATE MEDICATION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TRENDS;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; GERIATRICS; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; NEW ZEALAND; PHARMACOLOGY, CLINICAL; POLYPHARMACY; POTENTIALLY INAPPROPRIATE MEDICATION LIST; RISK FACTORS; TIME FACTORS;

EID: 84929026445     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000368191     Document Type: Article

References (30)

1. Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC: Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2012; 5: CD008165.
2. Gnjidic D, Hilmerv SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, McLachlan AJ, Abernethy DR, Banks E, Le Couteur DG: High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 2012; 91: 521-528.
3. Haider SI, Johnell K, Weitoft GR, Thorslund M, Fastbom J: The influence of educational level on polypharmacy and inappropriate drug use: A register-based study of more than 600,000 older people. J Am Geriatr Soc 2009; 57: 62-69.
4. Gnjidic D, Le Couteur DG, Pearson S-A, McLachlan AJ, Viney R, Hilmer SN, Blyth FM, Joshy G, Banks E: High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health 2013; 13: 115.
5. Fulton MM, Allen ER: Polypharmacy in the elderly: A literature review. J Am Acad Nurse Pract 2005; 17: 123-132.
6. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R: Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55: 809-817.
7. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG: Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012; 65: 989-995.
8. Corsonello A, Pedone C, Corica F, Incalzi RA: Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag 2007; 3: 197-203.
9. Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, Gambassi G: Adverse drug reactions as cause of hospital admissions: results from the Italian group of pharmacoepidemiology in the elderly (GIFA). J Am Geriatr Soc 2002; 50: 1962-1968.
10. Flaherty JH, Perry HM 3rd, Lynchard GS, Morley JE: Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci 2000; 55:M554-M559.
11. Hilmer SN, Gnjidic D: The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85: 86-88.
12. Maher RL, Hanlon J, Hajjar ER: Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13: 57-65.
13. Nishtala PS, Narayan SW, Wang T, Hilmer SN: Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf 2014; 23: 753-758.
14. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002; 287: 337-344.
15. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S: Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: A cross-sectional analysis. Drugs Aging 2009; 26: 493-503.
16. Hovstadius B, Hovstadius K, Astrand B, Petersson G: Increasing polypharmacy-an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol 2010; 10: 16.
17. Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S: Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 2011; 20: 514-522.
18. Atkinson J, Salmond C, Crampton P: NZDep2013 Index of Deprivation. New Zealand, Ministry of Health, 2014.
19. Gokce Kutsal Y, Barak A, Atalay A, Baydar T, Kucukoglu S, Tuncer T, Hizmetli S, Dursun N, Eyigor S, Saridogan M, Bodur H, Canturk F, Turhanoglu A, Arslan S, Basaran A: Polypharmacy in the elderly: A multicenter study. J Am Med Dir Assoc 2009; 10: 486-490.
20. Bjerrum L, Sogaard J, Hallas J, Kragstrup J: Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54: 197-202.
21. The Pharmaceutical Management Agency (PHARMAC): Memorandum of understanding relating to the working relationship between PHARMAC and DHBs. http://www. pharmac.health.nz/about/accountabilitydocuments/ relationshipagreements (accessed March 17, 2014).
22. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association: JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl 5):v1-v52.
23. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997; 18: 736-753.
24. Eccles M, Freemantle N, Mason J: North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ 1998; 316: 1369-1375.
25. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, et al: Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail 1995; 1: 183-187.
26. Heart Failure Guidelines for Health Professionals. New Zealand, National Heart Foundation of New Zealand, 2009.
27. Vermeer NS, Bajorek BV: Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. J Clin Pharm Ther 2008; 33: 591-601.
28. Acute Coronary Syndrome Guidelines Working Group: Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006; 184: 1-32.
29. 2012 Writing Committee Members, Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines: 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2012; 126: 875-910.
30. Hilmer SN, McLachlan AJ, Le Couteur DG: Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007; 21: 217-230.